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Introduction 
Suppressor of cytokine signaling/cytokine-inducible
SH2 protein (SOCS/CIS) is a family of eight intracel-
lular proteins (SOCS 1-7, CIS) that regulate the
responses of immune cells to cytokines [1-6]. One of
the best characterized SOCS/CIS family members,
which play the pivotal role in many immunological
and pathological processes, is SOCS1 [1-8]. In vivo
and in vitro data introduce the role of SOCS1 protein
as tumor suppressor [9-11]. The molecular mecha-
nisms in various types of malignances by which
SOCS1 negatively regulate activation of innate and
adaptive immunity are connected with inhibition of the
JAKs/STAT1 (Janus family kinases/signal transducer
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Abstract: Suppressor of cytokine signaling 1 (SOCS1) is the key regulator of cytokine-mediated innate and adaptive immu-
nity. One of the molecular mechanisms of SOCS1 is connected with inhibition of TLR4-NFκB pathway. The relationships
among these molecules in laryngeal carcinoma are not exactly known. In this preliminary study we focused on their special
activity and role in regulation of development and progression of laryngeal carcinoma. To investigate NFκB (p65 subunit)
nuclear and cytoplasmic expression in 45 tumor samples of advanced laryngeal carcinoma IHC staining was performed. To
determine the mRNA expression levels of TLR4, IRAK1, TRAF6 and SOCS1 in isolated neoplasm cells and non-cancerous
adjacent mucosa epithelial cells RT-PCR was used. The invasiveness of laryngeal carcinomas was evaluated according to
tumor front grading, TFG, which included tumor-related features (cytoplasmic differentiation, nuclear polymorphism, num-
ber of mitoses) and adjacent stroma-related characteristics of the peripheral edge of tumor infiltration (mode of infiltration,
depth of invasion and plasmalymphocytic infiltration). The relationships between pT, pN status, the histological G grade, cer-
tain clinicopathological characteristics as well as postoperative observation time and the mRNA expression of the molecules
mentioned earlier were investigated. Significant differences of TLR4-NFκB pathway molecules and SOCS1 mRNA expres-
sion in laryngeal tumor cells and normal adjacent mucosa cells as well as significant interconnections of TLR4, SOCS1 and
NFκB(p65) in isolated tumor cells were obtained. This preliminary study demonstrated that the expression of SOCS1 and
TLR4-NFκB pathway molecules had a strong association with the aggressiveness of laryngeal carcinoma. Positive relation-
ships of TRAF6 in tumor margin cells with the histological grade and the mode of tumor invasion as well as the TFG total
score were highlighted. Significant positive correlations were found between the TLR4 in tumor central cells and the TFG
total score. Negative relationships of SOCS1 in tumor central cells with the histological grade were also noted. Significant
positive correlations were found between the  cytoplasmic NFκB(p65) and the mode of invasion as well as TFG total score.
Our findings confirmed the importance of SOCS1 and TLR4-NFκB pathway molecules as potential biomarkers for assess-
ment of the aggressive tumor phenotype in laryngeal carcinoma. 
Key words: laryngeal carcinoma, SOCS1 (suppressor of cytokine signaling 1), TLR4 (toll-like receptor 4), IRAK1 (inter-
leukin – 1 receptor – associated kinase), TRAF6 (TNF receptor-associated factor 6), NFκB (nuclear factor kappa B, p65
subunit), TFG (tumor front grading)
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and activator of transcription-1) pathway [1,3-5].
SOCS1 can inhibit JAK tyrosine kinase activity by the
kinase inhibitory region (KIR) in N-terminal domain
which act as pseudosubstrat. SOCS1 binds directly to
the JAK through its SH2 domain thus inhibits catalytic
activity [1]. On the other hand, a direct effect of SOCS1
on the toll-like receptor (TLR)/MD2 complex, NFκB
and c-Jun N-terminal kinases (JNK)/p38 pathway in
various types of hematopoietic cells including T and
NK T cells as well as antigen-presenting cells including
macrophages and dendritic cells has been also consid-
ered [1,4,6,12]. Induced proteasomal degradation of
p65 subunit of NF-κB is a potential mechanism of
TLRs signal suppression by SOCS proteins family
[7,8]. Upon TLRs stimulation MyD88 adaptor mole-
cules are recruited to the receptor complex via the TIR
domain and signaling molecules, among which are
interleukin- 1 receptor – associated kinase (IRAK1),
TNF receptor-associated factor 6 (TRAF6) and mito-
gen-activated protein kinase (MAPK), activate NFκB
[1,4,7,8,12]. However, little is known about the inter-
connections between SOCS1 and TLRs-NFκB signal
pathway in neoplastic cells of laryngeal carcinoma, the
association with clinicopathological characteristics and
the role in determining primary tumor's behavior. 
The aim of this preliminary study was to evaluate the
potential significance of SOCS1 and TLR4-NFκB path-
way molecules expression as potential biomarkers for
the aggressive tumor phenotype in laryngeal carcinoma.
Material and methods
Tissue samples, histological classification and morphological
features. For this preliminary study, archival paraffin-embedded tis-
sue samples from 24 patients (22 men, 2 women; age 47-81 yrs;
mean age 56±8 yrs) surgically treated for advanced laryngeal squa-
mous cell carcinoma (pT3 and pT4) were utilized. The criteria for
patient participation in this study were as follows: 1. histologically
confirmed diagnosis of carcinoma planoepitheliale, 2. primary sur-
gical resection of the larynx without receiving prior immuno-, radio-
or chemotherapy, 3. absence of distant metastases. All specimens
were confirmed by routine clinical diagnosis according to the UICC
TNM classification of 2003 for head and neck carcinomas [13].
Clinicomorphological characteristics of patients were listed in Table
1. Morphological estimation was performed on H&E-stained sec-
tions in the most invasive of the tumor, according to TFG classifica-
tion [14]. TFG features in the peripheral zones of the tumor were
assessed in at least five different regions of the peripheral part of the
tumor (magnification ×200, number of mitoses magnification ×400).
Each factor was graded according to a scale ranging from 1 to 4. The
total morphological TFG score was computed as the sum of six
parameters, with a maximum score of 24 points. According to the
TFG total score, tumors were divided into 5 groups: 6-9, 10-13, 14-
17, 18-21 and >22 TFG points. Certain characteristics of tumor front
grading, TFG, are shown in Table 2. Postoperative time of observa-
tion was 1 to 42 months; mean 14.1±13.9 months.
Non-cancerous/cancerous epithelium cells isolation. After radi-
cal laryngectomy, the surgical tissue specimens were excised asep-
tically immediately after operation from the least four tumor sites:
two from tumor centre, two from tumor margin and two sites of
non-cancerous adjacent laryngeal epithelium. Fragments of tissues
were washed with PBS for removal of contaminated blood and
next inserted in RPMI 1640 medium (Biomed, Poland) supple-
mented with antibiotics streptomycin/ penicillin/ gentamycin 1%
v/v (Sigma, Aldrich, Germany). The whole procedure was per-
formed on an ice plateau. Briefly, tissue specimens were cut with
surgical knife, minced with a scalpel. This was done in RPMI 1640
medium (Biomed, Poland) supplemented with antibiotics strepto-
mycin/ penicillin/ gentamycin 2%v/v (Sigma, Aldrich, Germany).
Fragments of tissues were then washed three times with Hanks
solution (Biomed Lublin, Poland). Next the tumor and normal
epithelial pieces were digested overnight (for 18h) in Nunc Petri-
dishes with 0.16mg/mL hyaluronidase (Sigma, Aldrich, Germany),
0.55mg/mL collagenase (Sigma, Aldrich, Germany) in the presence
of the antibiotics streptomycin/penicillin/gentamycin 1% v/v
(Sigma, Aldrich, Germany) in a 37°C, 5% CO2 (Cellstar Incubator).
The digested tissues were pressed gently through a 50-μm (mesh)
sieve (Sigma, Aldrich, Germany) with RPMI 1640 medium
(Biomed, Poland). Subsequently, the suspension was three times
washed with PBS (without Mg2+ and Ca2+) for 20 min in a 8°C by
centrifugation in MPW-350R centrifuge at 1800 rpm/500 rcf and
poured over by dyspase solution 2.4 U/mL, incubated for 30 min in
a 37°C and next resuspended in 1mL PBS. The concentration of
cells was estimated using a microscope and Bürker's chamber. To
get rid of the apoptotic and necrotic cells the columns of Magnetic
Cell Sorting Separator MACS (Miltenyi Biotec, Germany) and
Dead Cell Removal Kit was used. The recovered cells were checked
(typical epithelial morphology, immunohistochemical positive reac-
tions with policlonal antibodies [NCL-C11, Multi-Cytokeratin
402 K. Starska et al.
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2009:47(3): 402 (401-410) 
10.2478/v10042-009-0075-2
Table 1. Clinical characteristics of group studied 
4/5/6/8/10/13/18, RTU-D Novostatin Universal Detection Kit,
NCL-L-DAB Liquid DAB Substrate Kit; Novocastra UK]) and
counted for viability with trypan blue staining method. The isolated
laryngeal epithelial cells (TCC – tumor central cells, TMC – tumor
marginal cells, NCC – non-cancerous epithelial cells) were collect-
ed immediately after procedure and RNAlater RNA Stabilization
Reagent (QIAGEN GmbH, Hilden, Germany) was added to the cell
pellets. Cell pellets were stored at -80°C until isolation RNA. 
RNA extraction and reverse transcription PCR (RT-PCR)
analysis. Total RNA was isolated using TRI Reagent (Sigma-
Aldrich Co., USA) and quantified by spectrophotometry at 260
nm. RNA with a 260/280 nm ratio in the range 1.8-2.0 was con-
sidered high quality. RT-PCR was performed using a RNA PCR Kit
ver. 3.0 (Takara Shuzo Co., Ltd, Japan) according to the manufac-
turer's instructions. The TLR4, IRAK1, TRAF6, SOCS1  gene and
β-actin gene as standard were amplified using the specific primers:
TLR4(f) 5'-CTGCAATGGATCAAGGACCA-3', TLR4(r) 
5'-TCCCACTCCAGGTAAGTGTT-3', IRAK1(f)
5'-GACCAAGTATCTGAAAGACCTGGTG-3', IRAK1(r)
5'-TCAGCTCTGAAATTCATCACTTTC-3', TRAF6(f)
5'-TGATAGTGTGGGTGGAACTG-3', TRAF6(r)
5'-CTCCTTGGACAATCCTTCAG-3', SOCS1(f)
5'-ACCTTCTTGGTGCGCGAC-3', SOCS1(r)
5'-AAGCCATCTTCACGCTGAGC-3', β-actin(f)
5'-CGTGACATTAAGGAGAAGCTGTGC-3', β-actin(r)
5'-CTCAGGAGGAGCAATGATCTTGAT-3'. 
The thermal cycling parameters were 30 rounds of 1 min at 94°C,
1 min at 51°C (TLR4, IRAK1, TRAF6, SOCS1, β-actin), and 3
min at 72°C using a GeneAmp PCR System 9700 (Perkin-Elmer
Co, Shelton, USA). The size of amplified fragments was 622, 847,
445, 387 and 374 bp for TLR4, IRAK1, TRAF6, SOCS1 and β-
actin, respectively. After amplification 10 μL of PCR products
were combined with 1 μL of gel loading buffer and the mixture
was electrophoresed on 8% polyacrylamide gel
(acrylamide/bisacrylamide (30/2), 10% ammonium peroxydisul-
fate, 0.075% tetramethyl ethylenediamine, at 80 V for 3 hrs in Tris-
borate, EDTA, pH 8.0 (TBE) buffer. The gel was silver stained. To
exclude contamination of genomic DNA as a source for amplified
products, each reaction was also carried out without reverse tran-
scriptase. In addition, no template control was run for both the RT
and PCR stages for each of the primer sets and none showed any
visible PCR products. For qualitative and quantitative analysis of
silver nitrate stained gels the software program Gel-Pro® Analyz-
er 3.0 (Media Cybernetics, USA) was used. All RT-PCR reactions
were repeated 3 times for each sample. The integrated optical den-
sity (IOD) of the bands in a digitized picture was measured. TLR4
and IRAK1, TRAF6, SOCS1 gene expression was determined as
the ratio of TLR4, IRAK1, TRAF6 and SOCS1 to β-actin. 
Immunohistochemistry (IHC). Paraffin sections were mounted
onto SuperFrost slides, deparaffinized, then treated in a microwave
oven in a solution of citrate buffer, pH 6.0 for 30 minutes (2×5 min-
utes 360 W, 4×5 minutes 180 W) and transferred to distilled water.
Endogenous peroxidase activity was blocked by 0,3% hydrogen per-
oxide in distilled water for 30 minutes, and then sections were rinsed
with Tris-buffered saline (TBS, DakoCytomation, Denmark) and
incubated with monoclonal rabbit anti-human NFκB (p65 subunit)
antibody (IBL Co., LTD, Japan), dilution: 1:100. Afterwards EnVi-
sion+Systems-HRP for mouse and rabbit (DakoCytomation, Den-
mark) prepared according to the instructions of the manufacturer
were used. Visualisation was performed by incubating the sections in
a solution of 3,3'-diaminobenzidine (DakoCytomation, Denmark).
After washing, the sections were counter-stained with hematoxylin
and coverslipped. For each antibody and for each sample a negative
control were processed. Negative controls were carried out by incu-
bation in the absence of the primary antibody and always yielded neg-
ative results. Positive tissue control was used to indicate correctly
prepared tissues and staining techniques. Positive tissue control was
skin. One positive tissue control was included for each set of test con-
ditions in each staining run. NFκB(p65 subunit) protein was detected
in the cell cytoplasm and/or in the nucleus. The intensity of IHC stain-
ing (in at least five different regions) as a percentage of tumor cells
with NFκB(p65) cytoplasmic expression was scored using three-tier
system (ranks): 0 – none; 1 – weak to intermediate (<50% cells with
positive staining); 2 – strong (≥50% positive cells). The nuclear stain-
ing intensity was classified (ranks) as: 0 – negative; 1 – positive (cells
with positive staining). At least 10 high-power fields (magn. 40x)
were assessed for each specimen. All slides were assessed in three
independent sessions by two researchers.
Ethical issues. The study was performed with the approval of the
Bioethical Commission of the Medical University of Lodz and the
National Science Council, Poland (No RNN/15/03/KN).
Statistical analysis of data. The statistical calculations were
made by STATISTICA 5.0 (StatSoft, Inc. USA). None of the
parameters recorded in tumor material passed tests for being nor-
mally distributed (Kolmogorov-Smirnow test) and therefore non-
parametric statistical tests were used for analyzing the results
(Spearman's rank analysis; Mann-Whitney U test). P-values <0.05
were considered to be significant. 
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Table 2. Features used for tumor front grading and numeric score [14]
Results 
TLR4, IRAK1, TRAF6 and SOCS1 gene
expression in laryngeal epithelial cells.
Immunoexpression of cytoplasmic and nuclear
NFκB(p65) in laryngeal carcinoma specimens.
The relationships between TLR4-NFκB 
pathway molecules expression as well as
SOCS1 expression and NFκB(p65) 
immunostaining
Our results demonstrated that laryngeal cancerous
epithelial cells as well as non-cancerous adjacent
mucosa epithelial cells, used as a control, expressed
mRNA for TLR4, IRAK1, TRAF6 and SOCS1. To
investigate the differences between the expression of
TLR4, IRAK1, TRAF6 and SOCS1 in the various types
of epithelial cells, the RT-PCR results for a chosen pair
of epithelial cells were juxtaposed. The mean mRNA
content of studied molecules in epithelial neoplastic
cells and in normal adjacent mucosa epithelial cells is
introduced in Table 3. We observed significant differ-
ences in TRAF6 expression between non-cancerous
epithelial cells (NCC) and tumor marginal cells (TMC)
(p=0.02). Moreover, we noted significant differences in
TLR4, IRAK1 mRNA content between non-cancerous
epithelial cells (NCC) and tumor central cells (TCC)
(p=0.002 and p=0.04, respectively). Furthermore, we
found significant differences between SOCS1 expres-
sion in NCC and TMC (p=0.01) as well as in TCC of the
carcinoma infiltration (p=0.001). Representative
expression of TLR4, IRAK1, TRAF6 and SOCS1 in
TMC, TCC and NCC is shown in Figure 1. 
In the present study, we recorded cytoplasmic and
nuclear data of NFκB(p65) immunostaining separately,
taking into consideration the apparent biologic impor-
tance of NFκB localization. We noticed a trend towards
NFκB(p65) the excessive cytoplasmic reserve, along
with infrequent translocation into nucleus. Our experi-
ments confirmed the cytoplasmic NFκB(p65) (NFκB-c)
positive expression in 95.8% (23/24) of all tumor sam-
ples – 54.2% (13/24) cases had weak to intermediate
positive IHC staining (with IHC index of <50%) and
41.6% (10/24) cases had strong IHC positive staining
(with IHC index of ≥50%). The nuclear NFκB(p65)
(NFκB-n) positive expression in 33.3% (8/24) and neg-
ative IHC staining for NFκB-n in 66.7% (16/24) cases
of squamous cell laryngeal carcinoma were observed.
Representative IHC stainings for NFκB-c and NFκB-n
are shown in Figs. 2AB. To verify whether TLR4
expression, the first signal in TLR4-NFκB pathway, as
well as SOCS1 expression, a negative regulator of this
cascade, can determine NFκB(p65) expression in cyto-
plasm and nucleus of squamous cell laryngeal carcino-
ma cells or not, we juxtaposed the level of mRNA for
these molecules with NFκB(p65) immunoexpression.
Our results indicated a significant dependence of both
NFκB-c (r=0.54, p=0.04) and NFκB-n (r=0.55, p=0.03)
on TLR4 expression in border cancerous cells from the
most invasiveness part of the neoplastic infiltration. The
tumors with a high TLR4 expression had more intensive
NFκB(p65) immunoexpression in either cytoplasm or
nucleus of the neoplastic cells. Our study did not
revealed any other interconnections of NFκB(p65) with
TLRs-NFκB pathway molecules mRNA content. For
neither NFκB-c and NFκB-n nor SOCS1 there was a
statistically significant association between IHC stain-
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Table 3. Mean expression of TLR4, IRAK1, TRAF6 and SOCS1 in various types of laryngeal epithelial cells 
TMC – tumor border cells; TCC – tumor central cells; NNC – normal adjacent mucosa cells
Fig. 1. Representative TLR4, IRAK1, TRAF6 and SOCS1 mRNA
expression in tumor border epithelial cells (TMC), tumor central
epithelial cells (TCC) and normal adjacent mucosa epithelial cells
(NCC) of squamous cell laryngeal carcinoma. 
ing and mRNA expression level, in both TMC and TCC.
However, we observed tends to increase of NFκB
immunoexpression in tumors with a lower SOCS1
expression but these association did not reached a sta-
tistical significant level (r=-0.38 for relationship
between NFκB-c and SOCS1 in TMC, r=-0.47 for
NFκB-c and SOCS1 in TCC and r=-0.47 for NFκB-n
and SOCS1 in TCC, respectively). Expression of TLR4
mRNA in TMC from the most aggressive zone of the
neoplastic infiltration depending on the NFκB-c and
NFκB-n immunostaining is shown in Fig. 3AB.
The relationships of TLR4, IRAK1, TRAF6 
and SOCS1 gene expression in border (TMC)
and central (TCC) neoplastic tumor cells
with clinicopathological parameters
of the laryngeal carcinoma.
To check whether TLR4-NFκB pathway molecules
and SOCS1 gene expression analyzed in neoplastic
border and central cells of the laryngeal tumor can
potentially determine clinicomorphological features,
the RT-PCR results were juxtaposed with the TFG total
score and chosen parameters of TFG classification.
The most numerous group of laryngeal carcinomas
were advanced tumors (pT3 and pT4) characterized by
G2 histological grade – 79.2% (19/24). In 4.2% (1/24)
cases G1 and in 16.6% (4/24) cases G3 status were
also confirmed. Diffuse growth of tumor infiltration
and indistinct tumor front borderlines were most often
seen in neoplasms group studied – 41.7% (10/24) and
41.7% (10/24), respectively. Less marked borderlines
of tumor infiltration were characteristic for carcinomas
in 16.6% (4/24) cases. In 8.3% (2/24) cases 10-13
points, in 66.7% (16/24) cases 14-17 points and in
25.0% (6/24) cases 18-21 points of total TFG score in
group studied were noted. Our study revealed a posi-
tive correlation between TRAF6 gene expression in
TMC and histopathological differentiation G of the
tumor (r=0.64, p=0.006). Tumors characterized by a
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Fig. 2. Representative immunohistochemi-
cal staining (IHC) for cytoplasmic NFκB
(NFκB-c) and nuclear NFκB (NFκB-n) in
laryngeal carcinoma tissues. (A) IHC for
NFκB-c with index of  ≥50% (character-
ized by dark grey cytoplasm of tumor
cells). Original magnification, ×200. 
(B) Positive IHC staining for NFκB-n
(characterized by black nuclei of tumor
cells). Original magnification, ×300.
higher G status demonstrated a higher TRAF6 mRNA
content. Our study also confirmed the presence of a
significant relationship between TRAF6 expression in
TMC and mode of tumor infiltration (r=0.56, p=0.02).
A higher TRAF6 gene expression was associated with
a diffuse mode of invasion with no distinct borderline.
We also found that TRAF6 mRNA status in TMC had
significant effect on TFG total score for advanced
squamous cell laryngeal carcinomas (pT3-T4) (r=0.59,
p=0.01). No relationships of statistical significance
were recorded between TLR4, IRAK1, SOCS1 gene
expression in TMC and other clinicomorphological
parameters. However, we observed tends to increase of
the malignant potential and aggressiveness of the
tumor, estimated according to TFG total results with a
low SOCS1 gene expression in TMC (r=-0.38), but
this association did not reach a statistical significant
level. Interestingly, in our study carcinomas character-
ized by a higher TLR4 mRNA content in border neo-
plasm cells manifested a lower pT stage (r=-0.37) and
a less intensive depth of tumor invasion (r=-0.40).
Similarly, neoplasms with a higher SOCS1 mRNA
level in TMC had a lower TFG total score (r=-0.39).
Our experiments have confirmed the presence of a sig-
nificant relationship between TLR4 gene expression in
TCC and TFG total score for advanced squamous cell
laryngeal carcinoma (pT3-T4) (r=0.69, p=0.009). The
group of patients with higher tumor front grading
results exhibited higher TLR4 expression. We also
found that SOCS1 mRNA content in TCC had signifi-
cant effect on histological differentiation G (r=-0.55,
p=0.04). There, tumors with a low histopathological
grade had a higher SOCS1 mRNA content. For neither
IRAK1 nor TRAF6 there was a statistically significant
association between mRNA expression levels in TCC
and other clinicopathological features. However, we
observed tends to increase proliferative and aggressive
potential of laryngeal carcinomas with a high TRAF6
gene expression in TCC. Tumors with a higher TRAF6
mRNA content in central neoplasm cells were charac-
terized by a higher status of tumor infiltration estimat-
ed according to the TFG classification (r=0.42).
Expression of chosen molecules of TLR4-NFκB path-
way and SOCS1 in TMC and TCC depending on the
clinicopathological characteristics is shown in Figure
4ABCD.
The relationships of NFκB-c and NFκB-n
immunoexpression in laryngeal tumor tissues
with clinicopathological parameters 
of the laryngeal carcinoma.
To check whether NFκB(p65) immunoexpression in
tissues of squamous cell laryngeal carcinoma can
determine clinicomorphologic tumor features, the IHC
results of NFκB-c and NFκB-n were juxtaposed with
the TFG total score and chosen parameters of the TFG
classification. Our data demonstrated a significant cor-
relation between NFκB-c and tumor front grading total
results (r=0.30 and p=0.04). The presence of
immunostaining for NFκB(p65) in cytoplasm of the
tumor tissue was connected with a higher an aggres-
sive potential of the neoplasm determined by a higher
cumulative TFG result. In addition we found that
NFκB-c expression had significant effect on the mode
of tumor invasion (r=0.34, p=0.02). The presence of
NFκB-c immunoexpression was associated with a dif-
fuse mode of invasion characterized by no distinct bor-
derline. Our results also indicated a significant differ-
ences in total TFG result and the mode of invasion
between laryngeal tumors with negative (group 0) and
positive (group 1 and 2) NFκB-c expression in tumor
tissue (p=0.04 for TFG and p=0.02 for type of tumor
infiltration, respectively). Moreover, we recorded a
positive relationship between NFκB-n immunohisto-
chemical staining in cellular nuclei and histopatholog-
ical differentiation G of the tumor. This result reached
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Fig. 3. (A) TLR4 mRNA expression in TMC from advanced
tumors (pT3-pT4) depending on the NFκB-c IHC staining (r=0.54,
p=0.04); (B) TLR4 mRNA expression in TMC from advanced
tumors (pT3-pT4) depending on the NFκB-n IHC staining (r=0.55,
p=0.03). 
border-line statistical significance (r=0.28, p=0.05).
We noticed that tumors with a low morphological dif-
ferentiation of the neoplasm front had a positive
NFκB-n expression. Differences characterized various
G status with negative and positive IHC of NFκB-n
also reached border-line statistical significance
(p=0.05). No relationships of statistical significance
has been recorded of NFκB-c and NFκB-n immunoex-
pression in laryngeal tumor tissues with other clinico-
pathological parameters of the laryngeal carcinoma. 
Discussion
SOCS1 protein has been shown to participate in lots of
important regulatory mechanisms in immunocompe-
tent cells and play the important role in many immuno-
logical and pathological processes [1,4,6,9,12]. In sev-
eral reports SOCS/CIS protein family emerge as key
physiological regulators of cytokine responses, includ-
ing those that regulate the inflammatory responses by
TLR and NFκB signals regulation [1,4,6,15]. What is
important, recent reports introduce the function of
SOCS/CIS protein family in the development and pro-
gression of various types of malignancies. These
results indicate a pivotal role of SOCS and accompa-
nying pathway signaling molecules in the regulation of
cellular growth and differentiation [1,9-11,16]. The
potential molecular mechanism of SOCS1 is connect-
ed with inducing TLR4, IRAK1, TRAF6 and MAPK
signaling suppression as well as the proteasomal
degradation of p65 subunit of NFκB [1,4,7,8,12].
Interactions of SOCS protein with various other sig-
naling molecules like JAKs/STAT1 pathway as well as
FAK, IRS1/2 and vav are also introduced [1,3,4,7,8,
17-19]. The crosstalk among TLRs-NFκB pathways
molecules and activation-dependent induction of
effector cells were discussed in the literature, but these
mechanisms remain unclear and it may cause diver-
gent conclusions [3,4]. Our results confirm activity of
SOCS1 and TLRs-NFκB signaling molecules genes in
laryngeal neoplastic tissue. Our data are consistent
with reports introducing TLRs utility to mediate the
activation of NFκB and indirect regulation of the tran-
scription process of the genes connected with apopto-
sis, cell cycle, proliferation, secretion of proinflamma-
tory and angiogenic cytokines as well as growth fac-
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Figure 4. Expression of chosen molecules of TLR4-NFκB pathway and SOCS1 in TMC and TCC depending on the clinicopathological
characteristics in advanced cases of laryngeal carcinoma (pT3-T4); (A) TRAF6 mRNA expression in TMC depending on the histological
differentiation G (r=0.64, p=0.006); (B) TRAF6 mRNA expression in TMC depending on the mode of invasion of tumors (r=0.56,
p=0.02); (C) TLR4 mRNA expression in TCC depending on the tumor front grading total score (r=0.69, p=0.09); (D) SOCS1 mRNA
expression in TCC depending on the histological differentiation G (r= -0.55, p=0.04). 
tors also in neoplasms [1,20,21]. Only single studies
do not confirm role of TLRs in activity of NFκB path-
way (22). SOCS proteins are introduced as tumor sup-
pressors which overexpression is linked with decreas-
ing in aggressive and metastatic potential due to inhi-
bition of tumor cell proliferation [1,9-11,23]. 
In our study we did not confirmed relationship
between SOCS1 mRNA content and NFκB activity in
tumor tissue. These results are in agreement with data
of other researchers that also suggest that SOCS pro-
teins induced by TLR stimulation limit the extent of
TLR signaling by inhibiting type I IFN signaling but
not the main NFκB pathway [4,24]. These analyses of
the early signaling pathway downstream of TLR4
demonstrated that SOCS1 had no regulatory effect on
the activation or on the DNA binding capacity of
NFκB. We found however in the literature, other data
indicate the existence of mechanisms of the suppres-
sion of NFκB activity as a results of the indirect inhi-
bition the INFβ-JAK-STAT1-NFκB signaling rapidly
induced through the TRIF/IRF-3 (toll-interleukin-1
receptor domain-containing adapter inducing interfer-
on-beta/IFN regulatory factor) after TLR4 stimulation
and the direct degradation of NFκB p65 by SOCS1
[3,4]. This is in line with the reports in which data indi-
cate that SOCS1 is implicated in blocking TLRs sig-
naling in immunocompetent cells activated by TLR
agonists and negatively regulate not only the
JAK/STAT pathway, but also the TLR-NFκB one
[4,25]. Discrepancies in results reported on SOCS1
expression and on the relationship with NFκB may stem
from different methods used in respective studies and
the predominance of one of mentioned mechanisms. 
Little is known on association of SOCS1 and
TLRs-NFκB pathway molecules expression in tumor
cells with clinicopathological characteristics of the pri-
mary laryngeal carcinoma. Our results point to the
hypothesis that SOCS1 and TLRs-NFκB pathway
molecules mRNA expression in tumor cells potential-
ly determined tumor's behavior assessed according to
TFG parameters and linked to deregulated cell growth,
proliferation as well as aggressiveness of neoplastic
infiltration in patients with laryngeal carcinoma. We
observed that high TRAF6 mRNA content, the inter-
mediary molecule of TLRs-NFκB pathway, in tumor's
front neoplastic cells was a marker for more malignant
phenotype assessed by G status and mode of invasion.
Our research also showed that high expression of
TLR4 in neoplastic border cells was associated with
increased of tumor extensiveness estimated according
to pT stage and mode of invasion. From a review of the
literature we learned that TLR4 is also able to induce
JAK1-STAT1 signaling pathway by TRIF/IRF-3 path-
way and that STAT1 can function as a tumor suppres-
sor [1,26]. These findings led us to conclusion that
TLR4 stimulation effect in cancer cells is the results of
a balance between the two signals: TLRs-NFκB path-
way and JAK1-STAT1 pathway. Moreover, the mech-
anism of anti-tumor immunity via TLR4/MD2 com-
plex stimulation is also described in the literature [27].
These findings suggest that the induction of apoptosis
in human HNSCC cell lines is connected with p53-
independent pathway via TLR4 signaling. Interesting-
ly, we noticed tends to increase the aggressiveness of
the tumor according to TFG classification with low
SOCS1 gene expression in border neoplastic cells.
The similar relationships in tumor central cells were
statistically significant. We also included that the
more intensive immunostaining for NFκB in cyto-
plasm of the tumor front tissue the higher TFG total
score was observed. Similarly to our observations,
other reports also introduce evidence that SOCS/CIS
family as well as TLR4-NFκB pathway molecules
play the important role in determining tumor growth
and progression of neoplasm disease and that SOCS1
act as antioncogenic protein [1,9,28-32]. Unfortunate-
ly, it is difficult to find in the literature reports direct-
ly binding SOCS/CIS family and TLRs activation
with clinicopathological features of the tumor. Only in
single publications the researchers suggest that
mRNA expression level of SOCS and TLR4 genes
and these proteins confer an invasive behavior and
tumor progression to neoplastic cells [9,33,34,35].
The results of studies related to HNSCC cases fre-
quently introduce the role of the TLR4 in modulation
of MyD88 and IRAK4 expression as well as NFκB
signaling and confirm their relationship with the
tumor grade, proliferation and induction NFκB
translocation [35]. The other data show that activation
of SOCS1 is an indicator for outcomes in patients
with neoplastic disease and it can be connected with
regulation of STAT1 by SOCS1 [9]. Our study is one
of individual reports on the significance of SOCS1
and TLRs-NFκB pathway molecules mRNA content
and the relationship with tumor front grading in carci-
noma of the larynx. 
We also introduce our voice in discussions on the
importance of NFκB(p65) activity in determination of
tumor's aggressive potential in laryngeal carcinoma.
Our results show that NFκB immunoexpression in the
carcinoma infiltration can be a marker of an invasive
behavior of the neoplastic cells. This is in line with
data of other reports introducing the important role of
NFκB in the development of cancer [36-40]. In the lit-
erature, many researchers confirm a high transcription
activity of NFκB in neoplastic cells and a high propor-
tion with positive reaction in advanced tumors tissue
(36-40). According to recent reports, the activation of
NF-κB determined by the different methods used in
respective studies, emerge as an independent prognostic
marker connected with clinical and pathological charac-
teristic of the various types of neoplasms [36-40]. 
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Nevertheless, our study failed to demonstrate the
relationship of mRNA content of chosen proteins in
laryngeal neoplastic tissue with postoperative observa-
tion time. These results might be due to the fact that
only 54% patients from studied group have been cov-
ered by the postoperative observation (other patients did
not come forward in the research) and because seven
patients in this group have reported on follow-up exam-
ination only once during one month after laryngectomy.
However, we confirmed in our previous reports the exis-
tence of strong relationships between TFG results and
overall survival in large group of patients with laryngeal
squamous cell carcinoma [41]. Therefore, it allows us to
conclude that the presence of significant relationships of
TLR4-NFκB pathway molecules and SOCS1 gene
expression with clinicomorphological features accord-
ing to TFG, indirectly indicate that mRNA content of
mentioned proteins could be prognostic predictors,
although further studies are necessary. 
Taken together our findings contribute to a better
current understanding of the pathogenesis of squa-
mous cell laryngeal carcinoma and the function of
SOCS1 and TLR4-NFκB pathway molecules in this
type of neoplasm. Furthermore, if confirmed in larger
studies, determination of these proteins expressions
could be used as biomarkers for tumor proliferation
and aggressiveness. These findings could be helpful
for clinicians in the assessment and counseling of
patients affected by these cancers or for scientists to
consider new potential therapeutic targets for the treat-
ment of these tumors. 
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